Minireview: Mechanisms of growth hormone- mediated gene regulation

Molecular Endocrinology

Volumn 28, Issue 7, 2014, Pages 1012-1025

  Chia, Dennis J ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; GROWTH HORMONE RECEPTOR; STAT PROTEIN; STAT5B PROTEIN; TRANSCRIPTION FACTOR; CHROMATIN; HUMAN GROWTH HORMONE; SOMATOMEDIN C; STAT5 PROTEIN; STAT5B PROTEIN, HUMAN;

ADIPOSE TISSUE; BONE; CHROMATIN; EPIGENETICS; GENE; GENE CONTROL; GENE LOCUS; GENE TARGETING; GENETIC TRANSCRIPTION; HUMAN; IGF1 GENE; LIVER; MOLECULAR MECHANICS; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; ANIMAL; BIOSYNTHESIS; GENE EXPRESSION REGULATION; GENETICS; GROWTH, DEVELOPMENT AND AGING; METABOLISM; MOUSE; PHYSIOLOGY;

ANIMALS; CHROMATIN; GENE EXPRESSION REGULATION; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; LIVER; MAP KINASE SIGNALING SYSTEM; MICE; MUSCLE, SKELETAL; RECEPTORS, SOMATOTROPIN; STAT5 TRANSCRIPTION FACTOR; TRANSCRIPTION, GENETIC;

EID: 84903576507     PISSN: 08888809     EISSN: 19449917     Source Type: Journal    
DOI: 10.1210/me.2014-1099     Document Type: Review

References (162)

1. Salmon WD Jr, Daughaday WH. A hormonally controlled serum factor which stimulates sulfate incorporation by cartilage in vitro. J Lab Clin Med. 1956;116:408-419.
2. Le Roith D, Bondy C, Yakar S, Liu JL, Butler A. The somatomedin hypothesis: 2001. Endocr Rev. 2001;22:53-74.
3. Liu JP, Baker J, Perkins AS, Robertson EJ, Efstratiadis A. Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF receptor (Igf1r). Cell. 1993;75:59-72.
4. Powell-Braxton L, Hollingshead P, Warburton C, et al. IGF-I is required for normal embryonic growth in mice. Genes Dev. 1993; 7:2609-2617.
5. Woods KA, Camacho-Hübner C, Savage MO, Clark AJ. Intrauterine growth retardation and postnatal growth failure associated with deletion of the insulin-like growth factor I gene. N Engl J Med. 1996;335:1363-1367.
6. Allen DB, Cuttler L. Clinical practice. Short stature in childhood-challenges and choices. N Engl J Med. 2013;368:1220-1228.
7. Molitch ME, Clemmons DR, Malozowski S, Merriam GR, Vance ML, Endocrine Society. Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96:1587-1609.
8. Liu H, Bravata DM, Olkin I, et al. Systematic review: the safety and efficacy of growth hormone in the healthy elderly. Ann Intern Med. 2007;146:104-115.
9. Bartke A. Minireview: role of the growth hormone/insulin-like growth factor system in mammalian aging. Endocrinology. 2005; 146:3718-3723.
10. Suh Y, Atzmon G, Cho MO, et al. Functionally significant insulinlike growth factor I receptor mutations in centenarians. Proc Natl Acad Sci USA. 2008;105:3438-3442.
11. Milman S, Atzmon G, Huffman DM, et al. Low insulin-like growth factor-1 level predicts survival in humans with exceptional longevity [published online March 12, 2014]. Aging Cell. doi: 10.1111/acel.12213.
12. Guevara-Aguirre J, Balasubramanian P, Guevara-Aguirre M, et al. Growth hormone receptor deficiency is associated with a major reduction in pro-aging signaling, cancer, and diabetes in humans. Sci Transl Med. 2011;3:70ra13.
13. Jansson JO, Edén S, Isaksson O. Sexual dimorphism in the control of growth hormone secretion. Endocr Rev. 1985;6:128-150.
14. Yakar S, Liu JL, Stannard B, et al. Normal growth and development in the absence of hepatic insulin-like growth factor I. Proc Natl Acad Sci USA. 1999;96:7324-7329.
15. Yakar S, Rosen CJ, Beamer WG, et al. Circulating levels of IGF-1 directly regulate bone growth and density. J Clin Invest. 2002;110: 771-781.
16. LeRoith D, Yakar S. Mechanisms of disease: metabolic effects of growth hormone and insulin-like growth factor 1. Nat Clin Pract Endocrinol Metab. 2007;3:302-310.
17. Ooi GT, Cohen FJ, Tseng LY, RechlerMM, Boisclair YR. Growth hormone stimulates transcription of the gene encoding the acidlabile subunit (ALS) of the circulating insulin-like growth factorbinding protein complex and ALS promoter activity in rat liver. Mol Endocrinol. 1997;11:997-1007.
18. Vijayakumar A, Yakar S, Leroith D. The intricate role of growth hormone in metabolism. Front Endocrinol (Lausanne). 2011;2:32.
19. Kim YD, Li T, Ahn SW, et al. Orphan nuclear receptor small heterodimer partner negatively regulates growth hormone-mediated induction of hepatic gluconeogenesis through inhibition of signal transducer and activator of transcription 5 (STAT5) transactivation. J Biol Chem. 2012;287:37098-37108.
20. Schirra HJ, Anderson CG, Wilson WJ, et al. Altered metabolism of growth hormone receptor mutant mice: a combined NMR metabonomics and microarray study. PLoS One. 2008;3:e2764.
21. Fan Y, Menon RK, Cohen P, et al. Liver-specific deletion of the growth hormone receptor reveals essential role of growth hormone signaling in hepatic lipid metabolism. J Biol Chem. 2009; 284:19937-19944.
22. Sos BC, Harris C, Nordstrom SM, et al. Abrogation of growth hormone secretion rescues fatty liver in mice with hepatocytespecific deletion of JAK2. J Clin Invest. 2011;121:1412-1423.
23. Cui Y, Hosui A, Sun R, et al. Loss of signal transducer and activator of transcription 5 leads to hepatosteatosis and impaired liver regeneration. Hepatology. 2007;46:504-513.
24. Barclay JL, Nelson CN, Ishikawa M, et al. GH-dependent STAT5 signaling plays an important role in hepatic lipid metabolism. Endocrinology. 2011;152:181-192.
25. Kotzka J, Knebel B, Avci H, et al. Phosphorylation of sterol regulatory element-binding protein (SREBP)-1a links growth hormone action to lipid metabolism in hepatocytes. Atherosclerosis. 2010;213:156-165.
26. Qin Y, Tian YP. Preventive effects of chronic exogenous growth hormone levels on diet-induced hepatic steatosis in rats. Lipids Health Dis. 2010;9:78.
27. Waxman DJ, O'Connor C. Growth hormone regulation of sexdependent liver gene expression. Mol Endocrinol. 2006;20:2613-2629.
28. Sundseth SS, Alberta JA, Waxman DJ. Sex-specific, growth hormone-regulated transcription of the cytochrome P450 2C11 and 2C12 genes. J Biol Chem. 1992;267:3907-3914.
29. Zhang Y, Klein K, Sugathan A, et al. Transcriptional profiling of human liver identifies sex-biased genes associated with polygenic dyslipidemia and coronary artery disease. PLoS One. 2011;6: e23506.
30. Pennisi PA, Kopchick JJ, Thorgeirsson S, LeRoith D, Yakar S. Role of growth hormone (GH) in liver regeneration. Endocrinology. 2004;145:4748-4755.
31. Møller N, Jørgensen JO. Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. Endocr Rev. 2009;30:152-177.
32. Beshyah SA, Freemantle C, Thomas E, et al. Abnormal body composition and reduced bone mass in growth hormone deficient hypopituitary adults. Clin Endocrinol (Oxf). 1995;42:179-189.
33. Johansen T, Richelsen B, Hansen HS, Din N, Malmlöf K. Growth hormone-mediated breakdown of body fat: effects of GH on lipases in adipose tissue and skeletal muscle of old rats fed different diets. Horm Metab Res. 2003;35:243-250.
34. Zhao JT, Cowley MJ, Lee P, Birzniece V, Kaplan W, Ho KK. Identification of novel GH-regulated pathway of lipid metabolism in adipose tissue: a gene expression study in hypopituitary men. J Clin Endocrinol Metab. 2011;96:E1188-E1196.
35. Kelder B, Berryman DE, Clark R, Li A, List EO, Kopchick JJ. CIDE-A gene expression is decreased in white adipose tissue of growth hormone receptor/binding protein gene disrupted mice and with high-fat feeding of normal mice. Growth Horm IGF Res. 2007;17:346-351.
36. List EO, Berryman DE, Funk K, et al. The role of GH in adipose tissue: lessons from adipose-specific GH receptor gene-disrupted mice. Mol Endocrinol. 2013;27:524-535.
37. Berryman DE, Glad CA, List EO, Johannsson G. The GH/IGF-1 axis in obesity: pathophysiology and therapeutic considerations. Nat Rev Endocrinol. 2013;9:346-356.
38. Morikawa M, Nixon T, Green H. Growth hormone and the adipose conversion of 3T3 cells. Cell. 1982;29:783-789.
39. Corin RE, Guller S, Wu KY, Sonenberg M. Growth hormone and adipose differentiation: growth hormone-induced antimitogenic state in 3T3-F442A preadipose cells. Proc Natl Acad Sci U S A. 1990;87:7507-7511.
40. Gurland G, Ashcom G, Cochran BH, Schwartz J. Rapid events in growth hormone action. Induction of c-fos and c-jun transcription in 3T3-F442A preadipocytes. Endocrinology. 1990;127:3187-3195.
41. Salomon F, Cuneo RC, Hesp R, Sönksen PH. The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency. N Engl J Med. 1989;321:1797-1803.
42. Sotiropoulos A, Ohanna M, Kedzia C, et al. Growth hormone promotes skeletal muscle cell fusion independent of insulin-like growth factor 1 up-regulation. Proc Natl Acad Sci USA. 2006; 103:7315-7320.
43. Mavalli MD, DiGirolamo DJ, Fan Y, et al. Distinct growth hormone receptor signaling modes regulate skeletal muscle development and insulin sensitivity in mice. J Clin Invest. 2010;120:4007-4020.
44. Nordstrom SM, Tran JL, Sos BC, Wagner KU, Weiss EJ. Liverderived IGF-I contributes to GH-dependent increases in lean mass and bone mineral density in mice with comparable levels of circulating GH. Mol Endocrinol. 2011;25:1223-1230.
45. Edwall D, Schalling M, Jennische E, Norstedt G. Induction of insulin-like growth factor I messenger ribonucleic acid during regeneration of rat skeletal muscle. Endocrinology. 1989;124:820-825.
46. DeVol DL, Rotwein P, Sadow JL, Novakofski J, Bechtel PJ. Activation of insulin-like growth factor gene expression during workinduced skeletal muscle growth. Am J Physiol. 1990;259:E89-E95.
47. Musarò A, McCullagh K, Paul A, et al. Localized Igf-1 transgene expression sustains hypertrophy and regeneration in senescent skeletal muscle. Nat Genet. 2001;27:195-200.
48. Barton ER, Morris L, Musaro A, Rosenthal N, Sweeney HL. Muscle-specific expression of insulin-like growth factor I counters muscle decline in mdx mice. J Cell Biol. 2002;157:137-148.
49. Yakar S, Courtland HW, Clemmons D. IGF-1 and bone: New discoveries from mouse models. J Bone Miner Res. 2010;25:2543-2552.
50. DiGirolamo DJ, Mukherjee A, Fulzele K, et al. Mode of growth hormone action in osteoblasts. J Biol Chem. 2007;282:31666-31674.
51. Bikle DD, Sakata T, Leary C, et al. Insulin-like growth factor I is required for the anabolic actions of parathyroid hormone on mouse bone. J Bone Miner Res. 2002;17:1570-1578.
52. Zhao G, Monier-Faugere MC, Langub MC, et al. Targeted overexpression of insulin-like growth factor I to osteoblasts of transgenic mice: increased trabecular bone volume without increased osteoblast proliferation. Endocrinology. 2000;141:2674-2682.
53. Govoni KE, Wergedal JE, Florin L, Angel P, Baylink DJ, Mohan S. Conditional deletion of insulin-like growth factor-I in collagen type 1α2-expressing cells results in postnatal lethality and a dramatic reduction in bone accretion. Endocrinology. 2007;148: 5706-5715.
54. Brown RJ, Adams JJ, Pelekanos RA, et al. Model for growth hormone receptor activation based on subunit rotation within a receptor dimer. Nat Struct Mol Biol. 2005;12:814-821.
55. Herrington J, Carter-Su C. Signaling pathways activated by the growth hormone receptor. Trends Endocrinol Metab. 2001;12: 252-257.
56. Stark GR, Darnell JE. The JAK-STAT pathway at twenty. Immunity. 2012;36:503-514.
57. Levy DE, Darnell JE. Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol. 2002;3:651-662.
58. Woelfle J, Rotwein P. In vivo regulation of growth hormone-stimulated gene transcription by STAT5b. Am J Physiol Endocrinol Metab. 2004;286:E393-E401.
59. Chia DJ, Rotwein P. Defining the epigenetic actions of growth hormone: acute chromatin changes accompany GH-activated gene transcription. Mol Endocrinol. 2010;24:2038-2049.
60. Laz EV, Sugathan A, Waxman DJ. Dynamic in vivo binding of STAT5 to growth hormone-regulated genes in intact rat liver. Sex-specific binding at low-but not high-affinity STAT5 sites. Mol Endocrinol. 2009;23:1242-1254.
61. Udy GB, Towers RP, Snell RG, et al. Requirement of STAT5b for sexual dimorphism of body growth rates and liver gene expression. Proc Natl Acad Sci USA. 1997;94:7239-7244.
62. Holloway MG, Cui Y, Laz EV, Hosui A, Hennighausen L, Waxman DJ. Loss of sexually dimorphic liver gene expression upon hepatocyte-specific deletion of Stat5a-Stat5b locus. Endocrinology. 2007;148:1977-1986.
63. Rowland JE, Lichanska AM, Kerr LM, et al. In vivo analysis of growth hormone receptor signaling domains and their associated transcripts. Mol Cell Biol. 2005;25:66-77.
64. Vidal OM, Merino R, Rico-Bautista E, et al. In vivo transcript profiling and phylogenetic analysis identifies suppressor of cytokine signaling 2 as a direct signal transducer and activator of transcription 5b target in liver. Mol Endocrinol. 2007;21:293-311.
65. Flores-Morales A, Ståhlberg N, Tollet-Egnell P, et al. Microarray analysis of the in vivo effects of hypophysectomy and growth hormone treatment on gene expression in the rat. Endocrinology. 2001;142:3163-3176.
66. Ono M, Chia DJ, Merino-Martinez R, Flores-Morales A, Unterman TG, Rotwein P. Signal transducer and activator of transcription (Stat) 5b-mediated inhibition of insulin-like growth factor binding protein-1 gene transcription: a mechanism for repression of gene expression by growth hormone. Mol Endocrinol. 2007; 21:1443-1457.
67. Xu J, Keeton AB, Franklin JL, et al. Insulin enhances growth hormone induction of the MEK/ERK signaling pathway. J Biol Chem. 2006;281:982-992.
68. Liang L, Zhou T, Jiang J, Pierce JH, Gustafson TA, Frank SJ. Insulin receptor substrate-1 enhances growth hormone-induced proliferation. Endocrinology. 1999;140:1972-1983.
69. Ceseña TI, Cui TX, Piwien-Pilipuk G, et al. Multiple mechanisms of growth hormone-regulated gene transcription. Mol Genet Metab. 2007;90:126-133.
70. Doglio A, Dani C, Grimaldi P, Ailhaud G. Growth hormone stimulates c-fos gene expression by means of protein kinase C without increasing inositol lipid turnover. Proc Natl Acad Sci USA. 1989; 86:1148-1152.
71. Piwien-Pilipuk G, MacDougald O, Schwartz J. Dual regulation of phosphorylation and dephosphorylation of C/EBPβ modulate its transcriptional activation and DNA binding in response to growth hormone. J Biol Chem. 2002;277:44557-44565.
72. Ceseña TI, Cardinaux JR, Kwok R, Schwartz J. CCAAT/enhancer-binding protein (C/EBP) β is acetylated at multiple lysines: acetylation of C/EBPβ at lysine 39 modulates its ability to activate transcription. J Biol Chem. 2007;282:956-967.
73. Kang K, Robinson GW, Hennighausen L. Comprehensive metaanalysis of Signal Transducers and Activators of Transcription (STAT) genomic binding patterns discerns cell-specific cis-regulatory modules. BMC Genomics. 2013;14:4.
74. Rui L, Mathews LS, Hotta K, Gustafson TA, Carter-Su C. Identification of SH2-Bβ as a substrate of the tyrosine kinase JAK2 involved in growth hormone signaling. Mol Cell Biol. 1997;17: 6633-6644.
75. Su HW, Lanning NJ, Morris DL, Argetsinger LS, Lumeng CN, Carter-Su C. Phosphorylation of the adaptor protein SH2B1β regulates its ability to enhance growth hormone-dependent macrophage motility. J Cell Sci. 2013;126:1733-1743.
76. Barclay JL, Kerr LM, Arthur L, et al. In vivo targeting of the growth hormone receptor (GHR) Box1 sequence demonstrates that the GHR does not signal exclusively through JAK2. Mol Endocrinol. 2010;24:204-217.
77. Rowlinson SW, Yoshizato H, Barclay JL, et al. An agonist-induced conformational change in the growth hormone receptor determines the choice of signalling pathway. Nat Cell Biol. 2008;10: 740-747.
78. Jin H, Lanning NJ, Carter-Su C. JAK2, but not Src family kinases, is required for STAT, ERK, and Akt signaling in response to growth hormone in preadipocytes and hepatoma cells. Mol Endocrinol. 2008;22:1825-1841.
79. Johnson HM, Subramaniam PS, Olsnes S, Jans DA. Trafficking and signaling pathways of nuclear localizing protein ligands and their receptors. Bioessays. 2004;26:993-1004.
80. Conway-Campbell BL, Wooh JW, Brooks AJ, et al. Nuclear targeting of the growth hormone receptor results in dysregulation of cell proliferation and tumorigenesis. Proc Natl Acad Sci USA. 2007;104:13331-13336.
81. Conway-Campbell BL, Brooks AJ, Robinson PJ, Perani M, Waters MJ. The extracellular domain of the growth hormone receptor interacts with coactivator activator to promote cell proliferation. Mol Endocrinol. 2008;22:2190-2202.
82. Lincoln DT, Sinowatz F, Temmim-Baker L, Baker HI, Kölle S, Waters MJ. Growth hormone receptor expression in the nucleus and cytoplasm of normal and neoplastic cells. Histochem Cell Biol. 1998;109:141-159.
83. Flores-Morales A, Greenhalgh CJ, Norstedt G, Rico-Bautista E. Negative regulation of growth hormone receptor signaling. Mol Endocrinol. 2006;20:241-253.
84. Strous GJ, van Kerkhof P, Govers R, Ciechanover A, Schwartz AL. The ubiquitin conjugation system is required for ligand-induced endocytosis and degradation of the growth hormone receptor. EMBO J. 1996;15:3806-3812.
85. van Kerkhof P, Govers R, Alves dos Santos CM, Strous GJ. Endocytosis and degradation of the growth hormone receptor are proteasome-dependent. J Biol Chem. 2000;275:1575-1580.
86. Ram PA, Waxman DJ. Interaction of growth hormone-activated STATs with SH2-containing phosphotyrosine phosphatase SHP-1 and nuclear JAK2 tyrosine kinase. J Biol Chem. 1997;272:17694-17702.
87. Gu F, Dubé N, Kim JW, et al. Protein tyrosine phosphatase 1B attenuates growth hormone-mediated JAK2-STAT signaling. Mol Cell Biol. 2003;23:3753-3762.
88. Pilecka I, Patrignani C, Pescini R, et al. Protein-tyrosine phosphatase H1 controls growth hormone receptor signaling and systemic growth. J Biol Chem. 2007;282:35405-35415.
89. Choi JH, Kim HS, Kim SH, et al. Phospholipase Cgamma1 negatively regulates growth hormone signalling by forming a ternary complex with Jak2 and protein tyrosine phosphatase-1B. Nat Cell Biol. 2006;8:1389-1397.
90. Greenhalgh CJ, Rico-Bautista E, Lorentzon M, et al. SOCS2 negatively regulates growth hormone action in vitro and in vivo. J Clin Invest. 2005;115:397-406.
91. Zhang Y, Laz EV, Waxman DJ. Dynamic, sex-differential STAT5 and BCL6 binding to sex-biased, growth hormone-regulated genes in adult mouse liver. Mol Cell Biol. 2012;32:880-896.
92. Conforto TL, Zhang Y, Sherman J, Waxman DJ. Impact of CUX2 on the female mouse liver transcriptome: activation of femalebiased genes and repression of male-biased genes. Mol Cell Biol. 2012;32:4611-4627.
93. Chen Y, Lin G, Huo JS, et al. Computational and functional analysis of growth hormone (GH)-regulated genes identifies the transcriptional repressor B-cell lymphoma 6 (Bc16) as a participant in GH-regulated transcription. Endocrinology. 2009;150:3645-3654.
94. Kawamata N, Miki T, Ohashi K, et al. RecognitionDNAsequence of a novel putative transcription factor, BCL6. Biochem Biophys Res Commun. 1994;204:366-374.
95. Chang CC, Ye BH, Chaganti RS, Dalla-Favera R. BCL-6, a POZ/ zinc-finger protein, is a sequence-specific transcriptional repressor. Proc Natl Acad Sci USA. 1996;93:6947-6952.
96. Meyer RD, Laz EV, Su T, Waxman DJ. Male-specific hepatic Bcl6: growth hormone-induced block of transcription elongation in females and binding to target genes inversely coordinated with STAT5. Mol Endocrinol. 2009;23:1914-1926.
97. Leung KC, Johannsson G, Leong GM, Ho KK. Estrogen regulation of growth hormone action. Endocr Rev. 2004;25:693-721.
98. Leung KC, Doyle N, Ballesteros M, et al. Estrogen inhibits GH signaling by suppressing GH-induced JAK2 phosphorylation, an effect mediated by SOCS-2. Proc Natl Acad Sci USA. 2003;100: 1016-1021.
99. Leong GM, Moverare S, Brce J, et al. Estrogen up-regulates hepatic expression of suppressors of cytokine signaling-2 and-3 in vivo and in vitro. Endocrinology. 2004;145:5525-5531.
100. Huang Y, Kim SO, Yang N, Jiang J, Frank SJ. Physical and functional interaction of growth hormone and insulin-like growth factor-I signaling elements. Mol Endocrinol. 2004;18:1471-1485.
101. Gan Y, Zhang Y, Digirolamo DJ, et al. Deletion of IGF-I receptor (IGF-IR) in primary osteoblasts reduces GH-induced STAT5 signaling. Mol Endocrinol. 2010;24:644-656.
102. Ma F, Wei Z, Shi C, et al. Signaling cross talk between growth hormone (GH) and insulin-like growth factor-I (IGF-I) in pancreatic islet β-cells. Mol Endocrinol. 2011;25:2119-2133.
103. Gan Y, Zhang Y, Buckels A, et al. IGF-1R modulation of acute GH-induced STAT5 signaling: role of protein tyrosine phosphatase activity. Mol Endocrinol. 2013;27:1969-1979.
104. Thissen JP, Ketelslegers JM, Underwood LE. Nutritional regulation of the insulin-like growth factors. Endocr Rev. 1994;15:80-101.
105. Inagaki T, Lin VY, Goetz R, Mohammadi M, Mangelsdorf DJ, Kliewer SA. Inhibition of growth hormone signaling by the fasting-induced hormone FGF21. Cell Metab. 2008;8:77-83.
106. Ding X, Boney-Montoya J, Owen BM, et al. βKlotho is required for fibroblast growth factor 21 effects on growth and metabolism. Cell Metab. 2012;16:387-393.
107. Touvier T, Conte-Auriol F, Briand O, et al. LEPROT and LEPROTL1 cooperatively decrease hepatic growth hormone action in mice. J Clin Invest. 2009;119:3830-3838.
108. Wu S, Grunwald T, Kharitonenkov A, Dam J, Jockers R, De Luca F. Increased expression of fibroblast growth factor 21 (FGF21) during chronic undernutrition causes growth hormone insensitivity in chondrocytes by inducing leptin receptor overlapping transcript (LEPROT) and leptin receptor overlapping transcript-like 1 (LEPROTL1) expression. J Biol Chem. 2013;288:27375-27383.
109. Wu S, Levenson A, Kharitonenkov A, De Luca F. Fibroblast growth factor 21 (FGF21) inhibits chondrocyte function and growth hormone action directly at the growth plate. J Biol Chem. 2012;287:26060-26067.
110. Yamamoto M, Iguchi G, Fukuoka H, et al. SIRT1 regulates adaptive response of the growth hormone-insulin-like growth factor-I axis under fasting conditions in liver. Proc Natl Acad Sci USA. 2013;110:14948-14953.
111. Tronche F, Opherk C, Moriggl R, et al. Glucocorticoid receptor function in hepatocytes is essential to promote postnatal body growth. Genes Dev. 2004;18:492-497.
112. Engblom D, Kornfeld JW, Schwake L, et al. Direct glucocorticoid receptor-Stat5 interaction in hepatocytes controls body size and maturation-related gene expression. Genes Dev. 2007;21:1157-1162.
113. ENCODE Project Consortium, Bernstein BE, Birney E, Dunham I, Green ED, Gunter C, Snyder M. An integrated encyclopedia of DNA elements in the human genome. Nature. 2012;489:57-74.
114. Shen Y, Yue F, McCleary DF, et al. A map of the cis-regulatory sequences in the mouse genome. Nature. 2012;488:116-120.
115. Daughaday WH, Rotwein P. Insulin-like growth factors I and II. Peptide, messenger ribonucleic acid and gene structures, serum, and tissue concentrations. Endocr Rev. 1989;10:68-91.
116. Lowe WL Jr, Roberts CT Jr, Lasky SR, LeRoith D. Differential expression of alternative 5′ untranslated regions in mRNAs encoding rat insulin-like growth factor I. Proc Natl Acad Sci USA. 1987;84:8946-8950.
117. Chia DJ, Young JJ, Mertens AR, Rotwein P. Distinct alterations in chromatin organization of the two IGF-I promoters precede growth hormone-induced activation of IGF-I gene transcription. Mol Endocrinol. 2010;24:779-789.
118. Adamo ML, Ma X, Ackert-Bicknell CL, Donahue LR, Beamer WG, Rosen CJ. Genetic increase in serum insulin-like growth factor-I (IGF-I) in C3H/HeJ compared with C57BL/6J mice is associated with increased transcription from the IGF-I exon 2 promoter. Endocrinology. 2006;147:2944-2955.
119. Nolten LA, van Schaik FM, Steenbergh PH, Sussenbach JS. Expression of the insulin-like growth factor I gene is stimulated by the liver-enriched transcription factors C/EBP α and LAP. Mol Endocrinol. 1994;8:1636-1645.
120. Nolten LA, Steenbergh PH, Sussenbach JS. Hepatocyte nuclear factor 1 α activates promoter 1 of the human insulin-like growth factor I gene via two distinct binding sites. Mol Endocrinol. 1995; 9:1488-1499.
121. Nolten LA, Steenbergh PH, Sussenbach JS. The hepatocyte nuclear factor 3β stimulates the transcription of the human insulinlike growth factor I gene in a direct and indirect manner. J Biol Chem. 1996;271:31846-31854.
122. Thomas MJ, Kikuchi K, Bichell DP, Rotwein P. Rapid activation of rat insulin-like growth factor-I gene transcription by growth hormone reveals no alterations in deoxyribonucleic acid-protein interactions within the major promoter. Endocrinology. 1994; 135:1584-1592.
123. Bichell DP, Kikuchi K, Rotwein P. Growth hormone rapidly activates insulin-like growth factor I gene transcription in vivo. Mol Endocrinol. 1992;6:1899-1908.
124. Thomas MJ, Kikuchi K, Bichell DP, Rotwein P. Characterization of deoxyribonucleic acid-protein interactions at a growth hormone-inducible nuclease hypersensitive site in the rat insulin-like growth factor-I gene. Endocrinology. 1995;136:562-569.
125. Woelfle J, Billiard J, Rotwein P. Acute control of insulin-like growth factor-I gene transcription by growth hormone through Stat5b. J Biol Chem. 2003;278:22696-22702.
126. Kofoed EM, Hwa V, Little B, et al. Growth hormone insensitivity associated with a STAT5b mutation. N Engl J Med. 2003;349: 1139-1147.
127. David A, Hwa V, Metherell LA, et al. Evidence for a continuum of genetic, phenotypic, and biochemical abnormalities in children with growth hormone insensitivity. Endocr Rev. 2011;32:472-497.
128. Woelfle J, Chia DJ, Rotwein P. Mechanisms of growth hormone (GH) action. Identification of conserved Stat5 binding sites that mediate GH-induced insulin-like growth factor-I gene activation. J Biol Chem. 2003;278:51261-51266.
129. Eleswarapu S, Gu Z, Jiang H. Growth hormone regulation of insulin-like growth factor-I gene expression may be mediated by multiple distal signal transducer and activator of transcription 5 binding sites. Endocrinology. 2008;149:2230-2240.
130. Billiard J, Grewal SS, Lukaesko L, Stork PJ, Rotwein P. Hormonal control of insulin-like growth factor I gene transcription in human osteoblasts: dual actions of cAMP-dependent protein kinase on CCAAT/enhancer-binding protein delta. J Biol Chem. 2001;276: 31238-31246.
131. Chia DJ, Varco-Merth B, Rotwein P. Dispersed Chromosomal Stat5b-binding elements mediate growth hormone-activated insulin-like growth factor-I gene transcription. J Biol Chem. 2010; 285:17636-17647.
132. Odom DT, Dowell RD, Jacobsen ES, et al. Tissue-specific transcriptional regulation has diverged significantly between human and mouse. Nat Genet. 2007;39:730-732.
133. Santhanam M, Chia DJ. Hepatic-specific accessibility of igf1 gene enhancers is independent of growth hormone signaling. Mol Endocrinol. 2013;27:2080-2092.
134. Sanyal A, Lajoie BR, Jain G, Dekker J. The long-range interaction landscape of gene promoters. Nature. 2012;489:109-113.
135. Frayling TM, Timpson NJ, Weedon MN, et al. A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. Science. 2007;316:889-894.
136. Smemo S, Tena JJ, Kim KH, et al. Obesity-associated variants within FTO form long-range functional connections with IRX3. Nature. 2014;507:371-375.
137. Weedon MN, Cebola I, Patch AM, et al. Recessive mutations in a distal PTF1A enhancer cause isolated pancreatic agenesis. Nat Genet. 2014;46:61-64.
138. Pasquali L, Gaulton KJ, Rodríguez-Seguí SA, et al. Pancreatic islet enhancer clusters enriched in type 2 diabetes risk-associated variants. Nat Genet. 2014;46:136-143.
139. Maurano MT, Humbert R, Rynes E, et al. Systematic localization of common disease-associated variation in regulatory DNA. Science. 2012;337:1190-1195.
140. Clayton P, Bonnemaire M, Dutailly P, et al. Characterizing short stature by insulin-like growth factor axis status and genetic associations: results from the prospective, cross-sectional, epidemiogenetic EPIGROW study. J Clin Endocrinol Metab. 2013;98: E1122-E1130.
141. Murphy LJ, Bell GI, Friesen HG. Tissue distribution of insulin-like growth factor I and II messenger ribonucleic acid in the adult rat. Endocrinology. 1987;120:1279-1282.
142. Ling G, Sugathan A, Mazor T, Fraenkel E, Waxman DJ. Unbiased, genome-wide in vivo mapping of transcriptional regulatory elements reveals sex differences in chromatin structure associated with sex-specific liver gene expression. Mol Cell Biol. 2010;30: 5531-5544.
143. Zaret KS, Watts J, Xu J, Wandzioch E, Smale ST, Sekiya T. Pioneer factors, genetic competence, and inductive signaling: programming liver and pancreas progenitors from the endoderm. Cold Spring Harb Symp Quant Biol. 2008;73:119-126.
144. Isgaard J, Nilsson A, Vikman K, Isaksson OG. Growth hormone regulates the level of insulin-like growth factor-I mRNA in rat skeletal muscle. J Endocrinol. 1989;120:107-112.
145. Sadowski CL, Wheeler TT, Wang LH, Sadowski HB. GH regulation of IGF-I and suppressor of cytokine signaling gene expression in C2C12 skeletal muscle cells. Endocrinology. 2001;142:3890-3900.
146. Nielsen C, Gormsen LC, Jessen N, et al. Growth hormone signaling in vivo in human muscle and adipose tissue: impact of insulin, substrate background, and growth hormone receptor blockade. J Clin Endocrinol Metab. 2008;93:2842-2850.
147. Vikman K, Isgaard J, Edén S. Growth hormone regulation of insulin-like growth factor-I mRNA in rat adipose tissue and isolated rat adipocytes. J Endocrinol. 1991;131:139-145.
148. Isaksson OG, Jansson JO, Gause IA. Growth hormone stimulates longitudinal bone growth directly. Science. 1982;216:1237-1239.
149. Stratikopoulos E, Szabolcs M, Dragatsis I, Klinakis A, Efstratiadis A. The hormonal action of IGF1 in postnatal mouse growth. Proc Natl Acad Sci USA. 2008;105:19378-19383.
150. Wu Y, Sun H, Yakar S, LeRoith D. Elevated levels of insulin-like growth factor (IGF)-I in serum rescue the severe growth retardation of IGF-I null mice. Endocrinology. 2009;150:4395-4403.
151. Nilsson A, Isgaard J, Lindahl A, Dahlström A, Skottner A, Isaksson OG. Regulation by growth hormone of number of chondrocytes containing IGF-I in rat growth plate. Science. 1986;233: 571-574.
152. Isgaard J, Möller C, Isaksson OG, Nilsson A, Mathews LS, Norstedt G. Regulation of insulin-like growth factor messenger ribonucleic acid in rat growth plate by growth hormone. Endocrinology. 1988;122:1515-1520.
153. Reinecke M, Schmid AC, Heyberger-Meyer B, Hunziker EB, Zapf J. Effect of growth hormone and insulin-like growth factor I (IGF-I) on the expression of IGF-I messenger ribonucleic acid and peptide in rat tibial growth plate and articular chondrocytes in vivo. Endocrinology. 2000;141:2847-2853.
154. Gevers EF, Hannah MJ, Waters MJ, Robinson IC. Regulation of rapid signal transducer and activator of transcription-5 phosphorylation in the resting cells of the growth plate and in the liver by growth hormone and feeding. Endocrinology. 2009;150:3627-3636.
155. Wu S, Morrison A, Sun H, De Luca F. Nuclear factor-κB (NF-κB) p65 interacts with Stat5b in growth plate chondrocytes and mediates the effects of growth hormone on chondrogenesis and on the expression of insulin-like growth factor-1 and bone morphogenetic protein-2. J Biol Chem. 2011;286:24726-24734.
156. Wu S, Walenkamp MJ, Lankester A, Bidlingmaier M, Wit JM, De Luca F. Growth hormone and insulin-like growth factor I insensitivity of fibroblasts isolated from a patient with an IκBα mutation. J Clin Endocrinol Metab. 2010;95:1220-1228.
157. Sims NA, Clément-Lacroix P, Da Ponte F, et al. Bone homeostasis in growth hormone receptor-null mice is restored by IGF-I but independent of Stat5. J Clin Invest. 2000;106:1095-1103.
158. Smith SS, Kessler CB, Shenoy V, Rosen CJ, Delany AM. IGF-I 3′ untranslated region: strain-specific polymorphisms and motifs regulating IGF-I in osteoblasts. Endocrinology. 2013;154:253-262.
159. Elia L, Contu R, Quintavalle M, et al. Reciprocal regulation of microRNA-1 and insulin-like growth factor-1 signal transduction cascade in cardiac and skeletal muscle in physiological and pathological conditions. Circulation. 2009;120:2377-2385.
160. Kawai M, Delany AM, Green CB, Adamo ML, Rosen CJ. Nocturnin suppresses igf1 expression in bone by targeting the 3′ untranslated region of igf1 mRNA. Endocrinology. 2010;151:4861-4870.
161. Umayahara Y, Billiard J, Ji C, Centrella M, McCarthy TL, Rotwein P. CCAAT/enhancer-binding protein delta is a critical regulator of insulin-like growth factor-I gene transcription in osteoblasts. J Biol Chem. 1999;274:10609-10617.
162. McCarthy TL, Centrella M, Canalis E. Cyclic AMP induces insulin-like growth factor I synthesis in osteoblast-enriched cultures. J Biol Chem. 1990;265:15353-15356.